The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

ASH 2020: Overview of the current advances in treating aggressive NHL

Featured
Feb 4, 2021
Share:

During the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, the Lymphoma Hub spoke to Sonali Smith, The University of Chicago, Chicago, US. We asked about current advances in treating aggressive lymphomas.

ASH 2020: Overview of the current advances in treating aggressive NHL

Smith discusses emerging approaches for patients with aggressive lymphomas, who may not be eligible for transplantation or responsive to CAR T-cell therapy. These approaches include bispecific antibodies and antibody-drug conjugates.

Share: